ANCA ASSOCIATED SYSTEMIC VASCULITIS
Clinical trials for ANCA ASSOCIATED SYSTEMIC VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANCA ASSOCIATED SYSTEMIC VASCULITIS trials appear
Sign up with your email to follow new studies for ANCA ASSOCIATED SYSTEMIC VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…
Matched conditions: ANCA ASSOCIATED SYSTEMIC VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participa…
Matched conditions: ANCA ASSOCIATED SYSTEMIC VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Revolutionary In-Body CAR-T therapy targets autoimmune diseases
Disease control Recruiting nowThis early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and dest…
Matched conditions: ANCA ASSOCIATED SYSTEMIC VASCULITIS
Phase: PHASE1 • Sponsor: Therorna • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Engineered immune cells take on lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…
Matched conditions: ANCA ASSOCIATED SYSTEMIC VASCULITIS
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC